Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Censo Biotechnologies developed advanced iPSC-based technologies to generate human cells from diverse donors for use in drug discovery, toxicity testing, disease modeling, and personalized medicine. The company supported pharmaceutical R&D by providing contract research services and custom cell lines but did not itself advance proprietary therapeutics into clinical trials. In 2021 it merged with Axol Bioscience to form a leading provider of iPSC-derived products and services for neuroscience, immune cell, and cardiac modeling applications
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Censo Biotechnologies.